STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) ), a pharmaceutical company that develops candidate drugs for ...
STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) ), a pharmaceutical company that develops candidate drugs for ...
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Scientists say people who have experienced a brain bleed should be regularly screened for cognitive impairment.
The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.
4d
News Medical on MSNNeurofilament light as a translational biomarker from preclinical drug discovery to clinical applicationNeurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.
This is the year to be optimistic about Alzheimer’s disease says one of Australia’s leading dementia researchers.
Feb. 6, 2025 — A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect ... among Americans is 42%, more than double ...
The factor that tips you over the edge from being at risk for a disease to actually developing the disease is not always ...
Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to ...
There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results